A Phase 1 interventional study of empagliflozin and metformin (Glucophage®) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-27.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to establish bioequivalence of two fixed dose combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1] and low dose empagliflozin/500 mg metformin [Test 2]) and of the single tablets (medium dose empagliflozin tablets + Glucophage® 500 mg tablet [Reference 1] and low dose empagliflozin tablet + Glucophage® 500 mg tablet [Reference 2]) when administered together after a high fat, high caloric meal.
The assessment of safety and tolerability will be an additional objective of this trial.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
fix dose combination tablet after intake of a high fat, high caloric meal
Drug: empagliflozin and metformin
single tablets after intake of a high fat, high caloric meal
Drug: empagliflozin · Drug: metformin (Glucophage®)
fix dose combination tablet after intake of a high fat, high caloric meal
Drug: empagliflozin and metformin
single tablets after intake of a high fat, high caloric meal
Drug: metformin (Glucophage®) · Drug: empagliflozin
single tablet empagliflozin
single tablet metformin
single tablet metformin
single tablet empagliflozin
Drug pages: Empagliflozin · Metformin
FDC tablet empagliflozin and metformin
Drug pages: Empagliflozin · Metformin
FDC tablet empagliflozin and metformin
AUC0-∞ for Empagliflozin
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin
Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
AUC0-∞ for Metformin
AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin
Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Cmax for Empagliflozin
Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin
Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Cmax for Metformin
Cmax (maximum measured concentration of the analyte in plasma) for Metformin
Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
AUC0-tz for Empagliflozin
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin
Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
AUC0-tz for Metformin
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin
Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
| Milestone | FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500 | Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5 | FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500 | Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5 |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 5 | 6 | 6 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin
| nmol*h/L | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| AUC0-∞ for Empagliflozin | 2780 ± 16.1 | 2870 ± 17.3 | 1110 ± 15.7 | 1070 ± 19.2 |
AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin
| ng*h/mL | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| AUC0-∞ for Metformin | 5590 ± 19.0 | 5820 ± 21.8 | 5960 ± 18.0 | 6190 ± 19.5 |
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin
| nmol*h/L | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| AUC0-tz for Empagliflozin | 2740 ± 16.3 | 2830 ± 17.3 | 1080 ± 15.7 | 1040 ± 19.1 |
Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin
| nmol/L | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| Cmax for Empagliflozin | 294 ± 23.7 | 282 ± 27.4 | 109 ± 22.8 | 106 ± 22.5 |
Cmax (maximum measured concentration of the analyte in plasma) for Metformin
| ng/mL | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| Cmax for Metformin | 686 ± 14.1 | 718 ± 19.7 | 693 ± 12.8 | 743 ± 19.6 |
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin
| ng*h/mL | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| AUC0-tz for Metformin | 5480 ± 18.9 | 5720 ± 21.2 | 5820 ± 17.7 | 6110 ± 19.2 |
Collected over From study drug administration of 1 treatment period until study drug administration in the next treatment period or date of trial completion plus 1 day, up to 8 days (and up to 16 days for one subject only). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12.5 mg Empagliflozin and 500 mg Metformin as FDC | — | 0/21 (0%) | 3/21 (14.3%) |
| 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | — | 0/23 (0%) | 6/23 (26.1%) |
| 5 mg Empagliflozin and 500 mg Metformin as FDC | — | 0/23 (0%) | 3/23 (13%) |
| 5 mg Empagliflozin and 500 mg Metformin as Single Tablets | — | 0/20 (0%) | 2/20 (10%) |
| Event | 12.5 mg Empagliflozin and 500 mg Metformin as FDC | 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets | 5 mg Empagliflozin and 500 mg Metformin as FDC | 5 mg Empagliflozin and 500 mg Metformin as Single Tablets |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/21 | 3/23 | 2/23 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/21 | 2/23 | 2/23 | 2/20 |
| NauseaGastrointestinal disorders | 0/21 | 2/23 | 1/23 | 0/20 |
| VomitingGastrointestinal disorders | 0/21 | 2/23 | 0/23 | 0/20 |
Treated set, included all subjects that entered the study and had taken at least 1 dose of trial medication.
| Age, Continuous(years) | FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500 | Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5 | FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500 | Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5 | Total |
|---|---|---|---|---|---|
| Mean | 38.2 ± 8.6 | 30.8 ± 7.6 | 35.8 ± 10.5 | 37.5 ± 9.0 | 35.6 ± 8.9 |
| Sex: Female, Male(Participants) | FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500 | Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5 | FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500 | Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5 | Total |
|---|---|---|---|---|---|
| Female | 5 | 2 | 4 | 4 | 15 |
| Male | 1 | 4 | 2 | 2 | 9 |
The record gives a start of Apr 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Metformin